Gefitinib and Methotrexate to Treat Ectopic Pregnancies with a Pre-Treatment Serum hCG 1000–10,000 IU/L: Phase II Open Label, Single Arm Multi-Centre Trial()

BACKGROUND: Ectopic pregnancies are a leading cause of maternal mortality. Most are treated surgically. We evaluated the efficacy and safety of combining oral gefitinib (epidermal growth factor receptor inhibitor) with methotrexate to treat larger ectopic pregnancies. METHODS: We performed a phase I...

Descripción completa

Detalles Bibliográficos
Autores principales: Skubisz, Monika M., Tong, Stephen, Doust, Ann, Mollison, Jill, Johns, Terrance G., Neil, Peter, Robinson, Miranda, Bhattacharya, Siladitya, Wallace, Euan, Krzys, Nicole, Colin Duncan, W., Horne, Andrew W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085507/
https://www.ncbi.nlm.nih.gov/pubmed/29941341
http://dx.doi.org/10.1016/j.ebiom.2018.06.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085507/
https://www.ncbi.nlm.nih.gov/pubmed/29941341
http://dx.doi.org/10.1016/j.ebiom.2018.06.017

Ejemplares similares